SCHEMBL508796

SCHEMBL508796

CNCc1ccc(OC2CCCC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
TSHR P16473 1/20 0.62
ALOX12 P18054 1/20 0.57
HRH3 Q9Y5N1 4/20 0.51
HRH1 P35367 1/20 0.45
ACACB O00763 3/20 0.45
GRM2 Q14416 1/20 0.45
TPSAB1 Q15661 1/20 0.44
TPSD1 Q9BZJ3 1/20 0.44
TPSG1 Q9NRR2 1/20 0.44
NCF1 P14598 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507962 0.98 ALDH1A1 (0.60) ALDH1A1TSHRALOX12HRH3HRH1
SCHEMBL13958972 0.81 HRH3 (0.54) ALDH1A1TSHRALOX12HRH3ACACB
SCHEMBL11941068 0.79 ALDH1A1 (0.54) ALDH1A1TSHRALOX12HRH3HRH1
SCHEMBL8497080 0.79 ALDH1A1 (0.71) ALDH1A1TSHRALOX12HRH3ACACB
SCHEMBL250809 0.78 ALDH1A1 (0.61) ALDH1A1TSHRALOX12HRH3ACACB
SCHEMBL13766488 0.78 ALDH1A1 (0.53) ALDH1A1TSHRALOX12HRH3HRH1
SCHEMBL27949438 0.76 HRH1 (0.73) ALDH1A1TSHRALOX12HRH3HRH1
SCHEMBL2242868 0.76 PARP10 (0.55) ALDH1A1TSHRALOX12HRH3HRH1
SCHEMBL11935997 0.76 ALDH1A1 (0.55) ALDH1A1TSHRALOX12HRH3
SCHEMBL14244302 0.76 ALDH1A1 (0.54) ALDH1A1TSHRALOX12HRH3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 ALDH1A1 866/4885TSHR 170/4885ALOX12 1323/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A ALDH1A1 500/4885TSHR 143/4885ALOX12 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.